DEVA HOLDING |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.4 TRY | +1.56% |
|
-11.00% | +20.98% |
| 05-17 | Deva Holding A.S. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-12 | Tod's rises 17% on L Catterton bids to help owner's delisting plan | RE |
| Sales 2022 | 4.48B 139M 189M | Sales 2023 | 11.33B 353M 479M | Capitalization | 15.11B 471M 638M |
|---|---|---|---|---|---|
| Net income 2022 | 1.36B 42.36M 57.45M | Net income 2023 | 3.38B 105M 143M | EV / Sales 2022 | 3.55 x |
| Net Debt 2022 | 2.06B 64.25M 87.14M | Net Debt 2023 | 1.92B 59.93M 81.28M | EV / Sales 2023 | 1.5 x |
| P/E ratio 2022 |
10.2
x | P/E ratio 2023 |
4.46
x | Employees | 2,908 |
| Yield 2022 |
0.22% | Yield 2023 |
-
| Free-Float | 17.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.56% | ||
| 1 week | -11.00% | ||
| 1 month | +21.30% | ||
| 3 months | +15.33% | ||
| 6 months | +11.53% | ||
| Current year | +20.98% |
1 week
89.50
103.30
1 month
74.85106.00
Current year
67.05106.00
1 year
41.40106.00
3 years
21.50106.00
5 years
5.15106.00
10 years
1.88106.00
| Managers | Title | Age | Since |
|---|---|---|---|
Philipp Haas
CEO | Chief Executive Officer | - | 06-07-13 |
Mesut Çetin
DFI | Director of Finance/CFO | 45 | 08-03-13 |
Altug Uysal
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philipp Haas
CEO | Chief Executive Officer | - | 06-07-13 |
Mesut Çetin
DFI | Director of Finance/CFO | 45 | 08-03-13 |
Aysecik Haas
BRD | Director/Board Member | - | 13-05-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 91.4 | +1.56% | 1,690,235 |
| 24-05-30 | 90 | -1.59% | 1,292,147 |
| 24-05-29 | 91.45 | -4.64% | 1,774,577 |
| 24-05-28 | 95.9 | -0.31% | 2,043,778 |
| 24-05-27 | 96.2 | -6.33% | 2,728,299 |
Delayed Quote Borsa Istanbul, May 31, 2024 at 11:09 am
More quotes
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Companyâs product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.
Sector
Pharmaceuticals
Calendar
2024-06-24
- Ex-dividend day for final dividend
| 1st Jan change | Capi. | |
|---|---|---|
| +20.98% | 567M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- DEVA Stock
